Objective The aim of this study was to determine the economic burden from a societal perspective and the health-related quality of life (HRQOL) of patients with systemic sclerosis (SSc; scleroderma) in Europe. Methods We conducted a cross-sectional study of patients with SSc (involving both localised and systemic sclerosis) from Germany, Italy, Spain, France, the UK, Hungary and Sweden. Data on demographic characteristics, healthcare resource utilisation, informal care, labour productivity losses and HRQOL were collected from the questionnaires completed by patients or their caregivers. HRQOL was measured with the EuroQol 5-domain (EQ-5D) questionnaire. Results A total of 589 patients completed the questionnaire. The rate of patients with localised scleroderma, limited cutan and diffuse cutan SSc were 28, 68 and 4 %, respectively. Average annual costs varied from country to country and ranged from € 4607 to € 30,797 (reference year: 2012). Estimated direct healthcare costs ranged from € 1413 to € 17,300; direct non-healthcare costs ranged from € 1875 to € 4684 and labour productivity losses ranged from € 1701 to € 14,444. The mean EQ-5D index score for adult SSc patients varied from 0.49 to 0.75 and the mean EQ-5D visual analogue scale score was between 58.72 and 65.86. Conclusion The main strengths of this study lie in our bottom-up approach to costing and our evaluation of SSs patients from a broad societal perspective. This type of analysis is very unusual in the international literature on rare diseases in comparison with other illnesses. We
Introduction
Systemic sclerosis (SSc; scleroderma) is a multisystem, heterogeneous and progressive disorder of unknown origin with no effective treatment or cure, resulting in disability and reduced life expectancy. Clinical features of SSc differentiate the disease into the 'limited' (lcSSc) and 'diffuse' (dcSSc) variants. In addition, a distinct form of scleroderma, termed 'localised' scleroderma (also known as morphea) is characterised by skin thickening; however, visceral involvement is lacking in this subtype.
The incidence and prevalence of SSc vary from 0.6-19 to 4-242 cases per million inhabitants, respectively, depending on the methodological differences in case definition and ascertainment, the time period studied and/or differences in genetic and ethnic backgrounds [1] [2] [3] [4] [5] [6] [7] [8] [9] .
SSc affected approximately 3.5 in 10,000 people in the European Union (EU). This was equivalent to a total of around 179,000 people and is below the ceiling for orphan designation, which is 5 people in 10,000 [10] .
SSc is characterised by a disturbance that affects fibroblast function, causes microvascular disease and activates the immune system, culminating in fibrosis of the skin and internal organs. Scleroderma is associated with significant morbidity, including skin thickening, finger ulcers, joint contractures, gastrointestinal involvement, pulmonary hypertension, interstitial lung disease and renal failure, thereby causing functional disability, considerable pain, depressive symptoms, disfigurement and feelings of helplessness [11] . The leading causes of scleroderma-related deaths are heart and lung complications [12] .
The complexity of SSc, its chronic course and the lack of effective treatment demand long-term multidisciplinary support by specialised physicians, physio-and occupational therapists, dieticians and psychologists [13] . To monitor SSc progression and response to supportive treatments, self-completed generic instruments to measure health-related quality of life (HRQOL) such as the EQ-5D [14] or the Medical Outcomes Study Short Form 36 and physical function measures such as the Health Assessment Questionnaire-Disability Index [15] are increasingly used.
SSc involves biological, psychological and social dimensions in affected individuals, which explains its impact on economic and quality-of-life issues despite its low frequency. However, while some studies have provided information about the economic impact of SSc in terms of healthcare costs and lost productivity [16] [17] [18] [19] and the consequences of scleroderma for HRQOL [15, [20] [21] [22] [23] [24] [25] [26] , no studies have provided comparative information on these two issues at the European level.
The BURQOL-RD (Social Economic Burden and Health-Related Quality of Life in Patients with Rare Diseases in Europe) project provides both economic and HRQOL information on patients affected by SSc and their caregivers in several European countries [27] . Social/economic and HRQOL data are essential in order to characterise the burden of disease and to assess the outcomes of health policies and new interventions for both clinicians and health policy decision-makers at the local, regional, national and international levels.
This study provides the European results of the BUR-QOL-RD project for SSc and has two main objectives: (i) to estimate the social/economic costs in three dimensions of costs: direct healthcare costs, direct non-healthcare costs (formal and informal care), and labour productivity losses, and (ii) to assess HRQOL in patients with SSc in 2012.
Methods

Research design and subjects
This was a cross-sectional study of patients diagnosed with SSc who received outpatient care and were living in the community in Germany, Italy, Spain, France, the UK, Hungary and Sweden. All patients and caregivers were informed about the study objectives and data confidentiality and were asked to confirm their understanding of the study conditions and agree to participate. The fieldwork was carried out between September 2011 and April 2013; however, in each country, the recruitment period did not exceed 6 months. Cases were recruited from national and regional SSc patient associations and the Spanish national rare diseases registry (SpainRDR). The questionnaires were distributed by e-mail and post through patient organisations. The survey was completely anonymous as the patients were contacted by their patient organisation or registry and their answers were sent directly to the researchers without any identification data (name, address or e-mail).
Variables of interest
Demographic and clinical data were collected from patients previously diagnosed with SSc and their caregivers by selfcompleted questionnaires. The questionnaire was detailed enough to reduce both exaggeration and underestimation [28, 29] . To estimate resource utilisation, the questionnaire solicited information covering the 6-month period prior to the study (12 months for hospital admissions). Data for the preceding 6 months were extrapolated to the entire year. We considered 6 months to be an appropriate recall period [28, 29] . Patients were asked about reductions in work time (temporary and permanent sick leave or early retirement), and these data were used to estimate labour productivity losses. In addition, when care was provided by non-professional caregivers, they were asked about the informal care time. Information about HRQOL was collected from SSc patients and their main informal caregiver through the generic EuroQol 5-domain (EQ-5D) questionnaire [30] .
Costing methodology
We used the prevalence approach to estimate costs from a societal perspective. Disease prevalence takes into account all cases during a given year and all healthcare resources used for prevention, treatment and rehabilitation, plus other resources allocated (formal and informal care) or lost (labour productivity) in that year as a consequence of the illness in question. Prevalence-based cost-of-illness analysis has the advantage of including measurements of total annual healthcare expenditure, which is particularly relevant for chronic conditions such as SSc that require long-term treatment [28, 29, 31] . In this context, a bottom-up costing approach was used to estimate total and average annual costs [31] . Data on resource utilisation were collected for each patient. The resources used were multiplied by unit costs to estimate the annual cost per patient (reference year: 2012).
Direct healthcare costs
Direct costs were derived from healthcare utilisation. The value of healthcare resources were estimated from the use of resources (physical units) by patients (primary source) combined with the unit cost of each of them (secondary sources). Information about the number of hospital admissions, emergency visits, outpatient care (rehabilitation, medical tests, medical visits and home medical care) and use of devices was also obtained from the questionnaires. We applied local reference prices to the healthcare resource data to estimate the direct costs of illness. Unit costs were obtained from different databases on healthcare costs used in Europe (see Annex II of the ESM) and subsequently multiplied by the units of each resource used. Both primary and secondary sources, including published papers, reports and hospital accounting systems, were used.
Information regarding the medications used by patients with SSc was obtained from the questionnaires. The cost of drugs used by patients was calculated by determining the daily cost for each of the products used (based on the cost of each pack dispensed and the dose used) and then multiplied by duration of use. When no information concerning the number of units per pack was available, we assumed the largest pack-size was dispensed.
The costs of prescription drugs used were obtained from the list of drugs approved in Europe (see Annex II of the ESM).
Direct non-healthcare costs
We obtained data on social services (formal care) and informal care. Informal care is defined as the performance of tasks by non-professionals to help maintain or enhance patient autonomy. Therefore, informal services are defined as the set of tasks or care provided by non-professional caregivers, who are often relatives, but can also be friends or neighbours. Information about informal care was obtained from the questionnaires, specifically from the items concerning the time spent helping the patient with his or her basic activities of daily living and the time spent helping with the necessary instrumental activities of daily living (recall method). As a conservative criterion, and for preventing joint production, we have censored the time of care to a maximum of 16 h per day per caregiver (112 h per week) when the time of care reported exceeded this figure.
The approach used to value care hours was the proxy good method, which values time as an output. This method values the care provided by the informal caregiver with the assumption that if he or she did not provide it, he or she would have to be replaced by another person who could [32] . Therefore, we took into consideration the question of how much it would cost to replace an informal caregiver by hiring a professional carer [33] .
Formal care refers to the community care and home care provided by professionals. It may be publicly or privately funded, or a combination of the two. Information on formal paid care was obtained from the questionnaires. Data on unit costs were provided by different sources in Europe.
Loss of labour productivity
Data on loss of labour productivity were obtained from physical units-focussing on sick leave and early retirement due to scleroderma-and converted into monetary units using a human capital-based approach (see Annex II). According to human capital theory [34] , the average earnings (gross wages) of a worker can be considered a good proxy for labour productivity losses. Therefore, our calculations were based on average gross wage figures in the participating countries. Annual labour productivity losses were estimated for the year 2012.
Patient outcomes
Patient outcomes were obtained by means of self-completed questionnaires: the EQ-5D, the Barthel Index and the Zarit Burden Interview. The EQ-5D is a simple generic instrument developed by a multidisciplinary group of researchers [30] . This questionnaire has been validated in many countries in Europe and is commonly used in economic evaluation and health technology assessment [35] . Health-related quality of life (HRQOL) is defined in terms of five dimensions: mobility, self-care, everyday activities, pain/discomfort and anxiety/depression [36] . The values and utilities are assigned a score on a scale where 0 corresponds to death and 1 corresponds to perfect health, with negative values being possible. The second part of the EQ-5D consists of a vertical 20-cm, 0-100 Visual Analogue Scale (EQ VAS), where 0 represents the worst and 100 represents the best imaginable health state. Respondents mark a point on the scale to reflect their overall perception of health on the day of the interview.
The Barthel Index is a widely used tool to assess disability and measures a person's ability to perform ten basic activities of daily living, providing a quantitative estimate of the subject's degree of dependence [37] [38] [39] . It is easily applied, has a high degree of reliability and validity, is capable of detecting changes and is easy to interpret. The Barthel Index is recommended as the instrument of choice for measuring physical disability in both clinical practice and in public health research [38] .
Caregivers also completed the Zarit Burden Interview (22-item version), which measures caregivers' subjective burden. Each item is a statement that the caregiver is asked to respond to using a five-point scale, with options ranging from 0 (never) to 4 (nearly always) [40] . The total score ranges from 0 to 88, with scores under 21 corresponding to little or no burden and scores over 61 corresponding to severe burden.
Results
A total of 810 questionnaires (73 % of all questionnaires sent out) were completed by and collected from SSc patients. Of these, 221 were excluded from the study because the information they contained was insufficient or inadequate. Therefore, the valid sample totalled 589 patients (147 in Spain, 38 in Hungary, 65 in Germany, 145 in Italy, 24 in the UK, 23 in Sweden and 147 in France). Altogether 557 patients provided responses on the subtype of the disease. The majority suffered from systemic scleroderma (N = 455, 77 %), only 15 % of the sample had localised scleroderma, and 8 % of the patients did not inform about their subtype. The main characteristics of our sample are shown in Table 1 . In the pooled sample, patients had a mean age of 50 (range 45-54), and caregivers had a mean age of 52 (range 40-55). The total average time spent caregiving by the main caregiver (if there was at least one caregiver) was estimated at between 19 (Germany) and 54 h per week (Spain).
SSc-related healthcare costs, non-healthcare costs (formal and informal) and productivity losses are presented in Table 2 . Average annual cost per patient in 2012 was estimated at € 21,640, € 26,542, € 21,557, € 4607, € 30,797, € 12,728 and € 12,600 for patients in Spain, the UK, France, Hungary, Bulgarian, Germany, Sweden and Italy, respectively. Formal care had a minor weight in all countries analysed. Meanwhile, informal care had a major weight in Spain, Hungary and Italy and a lesser weight in France and the UK, and it was virtually non-existent in Sweden and Germany. The largest cost components were healthcare costs in Germany, Sweden, France, Spain, the UK and Italy and labour productivity losses in the UK, Germany, France and Spain (Fig. 1) .
With regard to the HRQOL of people affected by SSc, the EQ-5D index score (TTO tariff) was estimated at 0.68, 0.52, 0.49, 0.64, 0.75, 0.69 and 0.64 over 1 for adult patients in Spain, the UK, France, Hungary, Germany, Sweden and Italy, respectively ( Table 1 ). The EQ-5D visual analogue scale score was estimated at 62.84, 59.10, 58.72, 64.78, 61.49, 65.86 and 59.35 over 100 for adult patients in Spain, the UK, France, Hungary, Germany, Sweden and Italy, respectively (Table 1) . These scores are significantly lower than in the general population after controlling for age and gender [41] . The average Barthel Index score for patients from all countries reflected mild dependence. The burden for caregivers was mild to moderate (the average Zarit Burden Interview score was 27) ( Table 1) .
Discussion
The growing level of interest in cost-of-illness analysis suggests that its ability to help us understand the social impact of diseases may allow it to become a useful tool in designing public policies [42] . In spite of these limitations, we believe that this study represents the most complete and realistic costing to date of the burden of SSc patients performed in a European setting. The main strength of the study lies in its bottom-up approach to costing. In addition, the costs were estimated for a period of 1 year; therefore, they provide a more accurate picture of the medium-term burden of SSc.
Among rare diseases, SSc is a significant health problem with important social consequences that are being increasingly characterised in high-income countries [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] . The incidence and prevalence of SSc and its health and social consequences in terms of mortality, morbidity, economic costs and quality of life justify the attention received from health authorities and society in general. There is a lack of publicly driven research on the economic burden of SSc. A report carried out by the London School of Economics and Political Science within the framework of the BURQOL-RD project discovered certain correlations between the prevalence of the disease and the availability of cost-of-illness information [43] . Four studies detailing the cost of illness for SSc were found [16] [17] [18] [19] as well as one more describing the disease burden in Spain [44] . Annual mean costs per patient vary across countries; the estimated annual costs of SSc in Hungary were higher, € 9619 (2006 data from a tertiary care centre, the rate of patients with dcSSc 25 %, no patients with localised scleroderma were involved) [16] , costs in Canada in 2007 were $ 18,453 [17] and in Italy costs were € 11,074 in 2001 [18] .
This analysis highlights the importance of studying the economic consequences of SSc and interpreting the results in an international context. The results of our analysis provide insights into the distribution of the costs of SSc and the impact of SSc on national expenditure on healthcare. We show that in 2012, the estimated annual cost was € 21,640, € 26,542, € 21,557, € 4607, € 30,797, € 12,728 and € 12,600 per SSc patient in Spain, the UK, France, Hungary, Germany, Sweden and Italy, respectively. We found differences among countries regarding costs of specific resource types, in particular drugs (Spain and Germany), medical tests (the UK), medical visits (Germany, the UK and Sweden), hospitalisation (Germany and France) and informal care (Spain, the UK and Italy). Nonetheless, with the exception of Germany and Hungary, the direct cost of illness was in absolute numbers remarkably similar across countries. In addition to direct costs, SSc was also associated with large productivity losses for both patients and caregivers.
By separately analysing healthcare costs (26.4-77.6 % of the total cost of illness), non-healthcare costs (2.3-30.8 % of the total cost of illness) and labour productivity losses (13.5-54.4 % of the total cost of illness), we found that healthcare costs and labour productivity losses were the largest expenditures. The fact that productivity losses were high for SSc patients is not surprising in light of the average age of the participants (50 years), most of whom are in the labour market when their illness is diagnosed.
Informal caregiving also constituted a major cost component in all countries. We included informal care as a direct cost with the rationale that the care would have otherwise had to be provided by long-term care services. In fact, in the absence of informal care, our results suggest that many patients with SSc would require residence in an institutional setting.
HRQOL is another source of information that helps define the overall societal impact of a specific health problem. HRQOL can be a useful indicator for setting priorities and allocating healthcare and social resources together with other information sources such as incidence, prevalence, mortality and costs. What was striking was the scale of the differences in productivity losses across countries. While some of these differences can be explained by the disparity in wages from one country to another, other institutional features such as labour and social legislation may protect different numbers of people with rare diseases. While our work cannot explore the issue further, it should be considered as a future line of research.
A review of HRQOL instruments used for rare diseases was carried out as part of the BURQOL-RD project by the Swedish Institute for Health Economics [45] . Thirty articles on studies of HRQOL in patients with SSc were identified. The majority (21 articles) used generic measures; the Short Form 36 health survey was used most frequently, either alone or in combination with other instruments. For our study, it was important that the EQ-5D demonstrated good acceptability, feasibility and validity in SSc patients [21] . As the authors of the review pointed out, for purposes of outcome comparison between diseases, the research should be focussed on the psychometric aspects of preference-based generic instruments.
The average EQ-5D index score for adult patients with SSc was estimated at between 0.49 (France) and 0.75 (Germany). Patient HRQOL was significantly lower than general population reference values.
Knowledge of HRQOL is also needed to measure the effectiveness of health interventions in disease management. Despite the relatively low frequency of SSc, this diagnosis is characterised by a substantial economic and Drugs  4258  6796  289  493  145  121  181  296  3229  6424  358  1214  442  408   Medical tests  534  421  2826  2890  648  571  102  117  298  254  1223  1308  283  203   Medical visits  1610  2341  3528  2501  1077  1348  112  138  4529  5038  2803  4188  1350  1345   Hospitalizations  1509  3844  836  2166  5075 12,559  788  983  7951 27,152  2643  4661  3133  8836 HRQOL burden. SSc patients with severe disability (dependence) are likely to suffer greater loss of productivity compared to people with mild disability. The findings provided by the study have several limitations. Both the study sample and recruitment process limit the external validity of the study. However, other studies of SSc have used smaller sample sizes because of the low disease frequency and high rates of refusal to participate [16, 18] . Recruitment of patients with definite SSc from different European countries was driven by local patient associations and, although the sample was almost evenly distributed across severity and dependency levels, we could not guarantee the absence of selection bias, which occurs in most studies on rare diseases. The dcSSc subtype (which often requires more intensive care and costly therapies than the localised scleroderma and lcSSc subtypes) occurred only in the Hungarian and Swedish sample; hence, our results probably underestimate the overall disease related costs and are not relevant for dcSSc patients in five of the seven countries. There is also a potential recall bias, given that the patient-based data were obtained by questionnaire. Another limitation of this study is the fact that the costs of institutionalisation and long-term care were not included. Although nursing home availability in southern Europe is increasing, the actual use remains quite low, forcing most potential residents to receive home care. As the BURQOL-RD project studied other rare diseases and intended to make comparisons with the general population, to measure HRQOL and disability, we did not use disease-specific instruments or instruments specifically validated for SSc, such as the Scleroderma Health Assessment Questionnaire [46] . However, the use of such instruments should be considered in further research into SSc.
Lastly, our study used cross-sectional data. The ideal study would be a prospective longitudinal study of a cohort of people with SSc. However, this type of study was beyond our means. In fact, to our knowledge, no study into the cost of SSc of this nature has been conducted; thus, this is a challenge for future researchers, public authorities and patient associations.
Despite the limitations of cost-of-illness analysis studies, the governments of many countries in Europe continue to encourage researchers to conduct them. The reason is that decision-makers consider information about the financial impact of diseases to be a useful input for programme planning [47] . This information does not replace, but rather complements, epidemiological information on population-level health problems.
We have shown in this study that the healthcare costs of SSc are very substantial. However, other social costs, such as loss of labour productivity and formal and informal care, are even higher. Additionally, we have shown that disability is associated with greater social costs in SSc. A clear understanding is needed of the current patterns of resource use, costs and HRQOL in SSc patients so that health services planning can be suitably informed. Cost-ofillness studies need to be updated in order to properly reflect the economics of diseases and their changing cost structures. This will enable policy-makers to gain a better understanding of the factors that impact on SSc-related expenditure and will enable a better-informed distribution of resources.
We conclude that SSc incurs considerable societal costs, including very high economic costs and a deterioration in HRQOL. SSc involves significant hidden costs that society should be made aware of and should be considered in the design and implementation of support programmes for people who suffer from this disease and for their caregivers, and in the area of economic evaluation of new treatments. Social/economic costs and health-related quality of life in patients with scleroderma in Europe S115
